Acetylcholine^*

Sydney Brenner first reported the isolation of drug-resistant mutants of C. elegans; the drugs he tested were the cholinesterase inhibitor lannate and the acetylcholine receptor agonist tetramisole (Brenner, 1974). Since then, the use of cholinergic drugs for mutant isolation has been extremely useful. Many of the mutations identified by drug resistance turned out to be alleles of genes previously identified as Uncs (e.g., unc-17, unc-29), yet a significant number of the drug resistance mutations were in previously unidentified loci (e.g., snt-1, ric-8, lev-1).

Mutations in a large number of genes can confer resistance, and for many of these genes, null alleles are viable; thus mutant screens and selections have been quite productive (Lewis et al., 1980b; Nguyen et al., 1995; Miller et al., 1996). Many cholinergic drugs (some of which are mentioned in subsequent sections) have been used in the analysis of specific mutants and behaviors; however, the two that have had the most significant impact on C. elegans neurobiology are aldicarb and levamisole.

Although lannate was initially used for such studies (Brenner, 1974), and trichlorfon has also been used (Hosono et al., 1989), the carbamate acetylcholinesterase inhibitor aldicarb (see Figure 2) has become the reagent of choice for evaluation of the “Ric” phenotype (for Resistance to Inhibitors of Cholinesterase). There are more than 50 genes known which can mutate to confer a Ric phenotype. The direct consequence of inhibiting AChE is a buildup of synaptic ACh, and since ACh is the excitatory transmitter at neuromuscular junctions, the excess ACh causes a hypercontracted paralysis. In principle, there should be two major gene classes which can mutate to confer aldicarb resistance. A mutation which disrupts ACh reception or any portion of the postsynaptic response to ACh would be expected to confer resistance (the muscle wouldn't “know” or “care” that there was excess ACh on its doorstep). In addition, however, any mutation which disrupted ACh synthesis, vesicular loading or release would lead to less ACh being released by the motor neurons, so there wouldn't be as much ACh to build up in the first place. A third possibility, mutation of an acetylcholinesterase subunit, would presumably require a very specific gain-of-function mutation, and is expected to be extremely rare.

Operationally, there are two strategies to determine/assess resistance to aldicarb. One can measure behavioral impairment following “acute” exposure to aldicarb, for example, the percent of animals totally paralyzed after 4 hrs as a function of aldicarb concentration (Nonet et al., 1993), or the percent of animals totally paralyzed as a function of time at, e.g., 2 mM aldicarb (Schade et al., 2005). An alternative is to measure growth and development in the presence of aldicarb, i.e., “chronic” exposure (Nguyen et al., 1995; Miller et al., 1999). Most mutageneses have employed a selection scheme based on growth and reproduction in the presence of aldicarb.

Although a few of the Ric mutations clearly affect cholinergic targets (e.g., cha-1, unc-17, ric-3, described in subsequent sections), most of them are in genes involved in the release of all neurotransmitters. Thus, for example, the first mutations in snt-1 (synaptotagmin), snb-1 (synaptobrevin), and ric-8 (synembryn) were isolated in large-scale selections for aldicarb resistance (Nonet et al., 1993; Nonet et al., 1998; Miller et al., 2000). As a result, aldicarb resistance in C. elegans is often equated with decreased neurotransmitter release, an unfortunate oversimplification. Nevertheless, a number of successful forward genetic screens have identified many important presynaptic components (Nguyen et al., 1995; Miller et al., 1996; Yook et al., 2001), and a recent genome-scale reverse genetic approach using aldicarb to identify genes affecting synaptic function has been described (Sieburth et al., 2005).

In contrast to the Ric phenotype, mutants have been described with the opposite “Hic” phenotype (Hypersensitivity to Inhibitors of Cholinesterase); and while many mutants with reductions in transmitter release are associated with aldicarb resistance, a number of mutants with apparent elevated release of acetylcholine are characterized by hypersensitivity to aldicarb (Lackner et al., 1999; Miller et al., 1999; Nurrish et al., 1999; Miller and Rand, 2000; Reynolds et al., 2005; Schade et al., 2005).

A particularly fruitful use of aldicarb mutants has been in the elaboration of a G-protein-coupled regulatory network that regulates ACh release from the ventral cord motor neurons (see Heterotrimeric G proteins in C. elegans). A core pathway in this network includes RIC-8, Gα_q (EGL-30) and phospholipase Cβ (EGL-8) and leads to production of DAG, which stimulates transmitter release; loss-of-function mutations in these components lead to decreased locomotion, decreased egg laying, and aldicarb resistance (Miller et al., 1999; Lackner et al., 1999; Miller et al., 2000; Reynolds et al., 2005). Conversely, gain-of-function mutations in this core pathway lead to the opposite phenotypes: hyperactive locomotion and egg laying, and hypersensitivity to aldicarb. Negative regulators of this pathway include Gα₀ (GOA-1) and DAG kinase (DGK-1), which reduce DAG levels and reduce transmitter release; loss-of-function mutations in such negative regulators lead to hyperactivity and aldicarb hypersensitivity (Nurrish et al., 1999). Many of the mutants that defined this signaling network were either isolated on the basis of altered response to aldicarb, or their response to aldicarb provided critical data for the interpretation of their function(s).

Levamisole (see Figure 2) is a potent cholinergic agonist, and is often used as a pesticide. It leads to a hypercontracted paralysis of wild-type nematodes, usually followed by relaxation and death (Lewis et al., 1980b). Levamisole has been shown to bind specifically to one of the two receptor types present in body-wall muscle, and has therefore been an extremely valuable tool in the molecular and physiological analysis of C. elegans AChR subunits (see Behavior section of WormMethods) . Operationally, the sensitivity or resistance of a given strain may be determined by monitoring either the time-course of paralysis or the extent of body-shortening due to muscle hypercontraction. The majority of levamisole-resistance genes were identified in several large-scale mutageneses by Jim Lewis (Lewis et al., 1980b; Lewis et al., 1980a). Mutations in several genes conferred strong resistance to levamisole, and also a mild uncoordinated phenotype: the AChR subunit-encoding genes unc-29, unc-38, and unc-63, and the accessory protein encoding genes unc-50 and unc-74 (Lewis et al., 1980b). There were also mutations conferring mild resistance to levamisole and normal locomotion; these identified the receptor subunit-encoding genes lev-1 and lev-8, and the accessory protein encoding gene lev-10. These genes are all described below in Sections 6 and 8.

Choline acetyltransferase catalyzes the acetylation of choline by acetyl-Coenzyme A (see Figure 1). The C. elegans enzyme has been partially purified and characterized (Rand and Russell, 1985); it is similar to the vertebrate and Drosophila ChAT proteins. Immunolocalization studies indicate that most of the ChAT protein is synaptic, but some immunoreactivity appears to be generally cytoplasmic (J. Duerr and J. Rand, unpublished). The synaptic protein is associated with a vesicular compartment, most likely synaptic vesicles, because it was mislocalized in unc-104 mutants. Both the synaptic and the cytoplasmic staining were decreased in particular cha-1 mutant strains and increased in transgenic lines which overexpress ChAT (J. Duerr and J. Rand, unpublished).

The vesicular acetylcholine transporter was first cloned and characterized in C. elegans (Alfonso et al., 1993), where it was shown to be the product of the unc-17 gene. Structurally, the UNC-17 (VAChT) protein has 12 transmembrane domains, with cytoplasmic (i.e., extravesicular) N- and C-termini, and is closely related to the vesicular monoamine transporters (VMATs). Immunoreactivity with anti-UNC-17 antibody preparations in wild-type animals is punctate and colocalizes with the synaptic vesicle protein synaptotagmin, suggesting that UNC-17 is associated with synaptic vesicles (Alfonso et al., 1993). This punctate staining is mislocalized in unc-104 mutants, providing additional support to the conclusion that UNC-17 is an integral membrane protein of synaptic vesicles.

Although there are several formal criteria used by neurobiologists to determine if a neuron is cholinergic, the unofficial criterion is expression of ChAT. Operationally, this means either immunolocalization of ChAT or expression of a cholinergic reporter (discussed below). By such criteria, approximately 120 neurons in the C. elegans hermaphrodite are cholinergic. The majority of these cells are motor neurons. These include the AS, DA, DB, VA, VB, and VC motor neuron classes of the ventral nerve cord, the sublateral motor neuron classes SAA, SAB, SIA, SIB, SMB, and SMD (Rand and Nonet, 1997), and the HSN cells (Duerr et al., 2001).

Genetic and molecular studies showed that cha-1 and unc-17 were part of a complex gene locus and transcription unit, with the unc-17 gene nested in the long first intron of cha-1 (see Figure 3; Rand, 1989; Alfonso et al., 1994a). Thus, the sequential steps of acetylcholine synthesis and vesicle-loading are encoded by different genes within a single, complex transcription unit. Subsequent studies demonstrated that a similar nested structure of these genes is present in mammals and insects (Erickson et al., 1994; Kitamoto et al., 1998). This is now commonly called the cholinergic gene locus, or CGL, and is present in all metazoans thus far examined (Eiden, 1998). It is noteworthy that the genes encoding enzymes and transporters for other neurotransmitters are not organized in a comparable way.

As described below, the unc-17 promoter regulates the expression of both genes, and may therefore be considered as a “cholinergic” promoter.

unc-17 mutants were first described by Brenner (Brenner, 1974), and cha-1 mutants were described 10 years later (Rand and Russell, 1984). More than a dozen cha-1 alleles and more than 20 unc-17 alleles have now been described (Brenner, 1974; Rand and Russell, 1984; Hosono et al., 1985; Rand, 1989; Alfonso et al., 1993; Alfonso et al., 1994a; Alfonso et al., 1994b; Zhao and Nonet, 2000; Zhu et al., 2001). Hypomorphic cha-1 mutants (including animals homozygous for the reference p1152 allele) are coily, uncoordinated, and jerky in reverse; they are also small, slow-growing, and resistant to aldicarb (Rand and Russell, 1984). Null alleles of cha-1 are lethal - the animals hatch, but they are essentially immobile, and do not grow or feed (Rand, 1989; Alfonso et al., 1993). In general, the phenotypes of hypomorphic unc-17 mutants (including animals homozygous for the e245 reference allele) are similar to those of cha-1: animals are small, slow-growing, coiling Uncs, jerky in reverse, and resistant to cholinesterase inhibitors (Brenner, 1974; Rand and Russell, 1984). Null unc-17 mutants are lethal, with a phenotype quite similar to cha-1 null mutants (Alfonso et al., 1993). The lethality of unc-17 null mutants and the similarity of their phenotype to cha-1 nulls argue that vesicular loading is an obligatory step in ACh release.

The molecular analysis of the region has helped to explain some genetic anomalies. Even though in general, cha-1 mutations and unc-17 mutations behaved as two discrete complementation groups, there were a few mutations that failed to complement both cha-1 and unc-17 alleles (Rand and Russell, 1984). These fell into two classes, termed α and β. Fine-structure genetic mapping indicated that the single α allele mapped between cha-1 and unc-17, but the two β alleles mapped well to the right of both loci (Rand, 1989). Subsequent molecular analysis revealed that the α allele corresponds to a small deletion between unc-17 and cha-1 (Alfonso et al., 1994a), and the β mutations are in the promoter region upstream of the unc-17 coding sequence (D. Frisby and J. Rand, unpublished). The observed noncomplementation between the β mutations and cha-1 alleles confirms that the promoter region upstream of unc-17 drives both unc-17 and cha-1 transcription (see Figure 3).

Like the vesicular acetylcholine transporter, the plasma membrane choline transporter was first cloned and characterized in C. elegans (Okuda et al., 2000). The ChT protein (CHO-1) is a member of a class of sodium-dependent transporters with substrates such as glucose (SGLT1) and inositol (SMIT1). It is best modeled as a 13-transmembrane domain protein, with a short N-terminus oriented extracellularly, and an extended, C-terminus oriented into the cytoplasm (Apparsundaram et al., 2000; Wang et al., 2001). Assays performed in embryonic cell culture showed that the C. elegans CHO-1 transporter was sodium- and chloride-dependent, with an apparent K_m for choline of 0.66 μM, comparable to mammalian transporters (Matthies et al., 2006).

Reporter studies indicate that cho-1 is expressed in most or all cholinergic neurons (Matthies et al., 2006). Within these neurons, a CHO-1-GFP fusion protein was localized to synaptic regions and was associated with a vesicular compartment, because its localization was dependent on UNC-104 (Matthies et al., 2006). This is consistent with results from mammalian systems demonstrating that the choline transporter is localized to apparent synaptic vesicles (Ferguson et al., 2003).

The reference allele, tm373, is a precise 1695 bp deletion which eliminates more than half of the cho-1 coding sequence; it is almost certainly a null allele. Animals homozygous for tm373 are viable, and their growth and development appear to be normal. However, although cho-1 mutants have little difficulty crawling on agar, they swim somewhat more slowly that wild-type animals, and become paralyzed (“fatigued”) more quickly than wild-type animals during prolonged swimming in liquid (Matthies et al., 2006). It is tempting to speculate that there is enough endogenous choline and/or low-affinity choline uptake activity (see below) in the cho-1 mutant nerve terminals to support some ACh synthesis even without any high-affinity reuptake activity, and that this level of ACh synthesis is sufficient for locomotion in a calm environment. However, this level of ACh is not adequate to support the increased demands of vigorous swimming, and the cho-1 motor neurons appear to become depleted of transmitter. This provides genetic-based evidence for a functional coupling of choline transport and ACh synthesis, and supports previous models based on other methods (Jope and Jenden, 1980; Collier, 1988; Bussiere et al., 2001).

If choline is indeed rate-limiting for acetylcholine synthesis under some circumstances, what determines the availability of choline? In C. elegans, choline is synthesized in the form of phosphocholine through progressive N-methylation of phosphoethanolamine by the PMT-1 and PMT-2 methyltransferases (Palavalli et al., 2006). Choline may also be produced through cleavage of phosphatidylcholine by phospholipase D (PLD-1). Choline is thus a product of lipid metabolism and lipid turnover. The activities of these enzymes have not been analyzed in cholinergic neurons.

SNF-6 is a post-synaptic choline/acetylcholine transporter (Kim et al., 2004). It is a member of the family of plasma membrane transporters which includes the serotonin transporter (MOD-5), the dopamine transporter (DAT-1), and the GABA transporter (SNF-11). The only two substrates identified for SNF-6 were choline and acetylcholine; both substrates had comparable K_m values, but the V_max for choline was about seven times the V_max for acetylcholine (Kim et al., 2004). This appears to be a nematode-specific transport activity. The SNF-6 protein is expressed in muscles, and is preferentially localized to neuromuscular junctions. snf-6 mutants are somewhat uncoordinated and mildly hypersensitive to aldicarb. This transport activity may provide a mechanism for rapid clearance of synaptic ACh and/or choline during periods of high transmitter release.

Most species (and apparently C. elegans as well) also express several “low-affinity” choline transport activities with broad tissue distributions. The CTL proteins in mammals (corresponding to the chtl-1 gene product) are sodium-independent transporters of choline and other organic cations (O'Regan et al., 2000). There is also a family of at least five organic cation transport (OCT) proteins in mammals with broad, overlapping substrate specificities (including choline; Friedrich et al., 2001). C. elegans members of this family include OCT-1 (Wu et al., 1999), OCT-2 (listed in WormBase with no data), plus 3 or 4 others in WormPep which are mostly uncharacterized. The involvement, if any, of these transport activities in cholinergic function is unknown.

Biochemical analysis of C. elegans homogenates led to a complicated assortment of AChE forms with different molecular weights, subunit composition, and hydrophobicity; however, three classes of AChE activity (A, B, and C) could be distinguished on the basis of substrate affinity, inhibitor specificities, and detergent sensitivities (Johnson and Russell, 1983; Kolson and Russell, 1985). Vertebrates express two families of cholinesterase activity, the “true” acetylcholinesterases and the “pseudo” or butyrylcholinesterases. However, the three C. elegans AChE activity classes do not correspond in any clear way to the vertebrate enzyme classes (Johnson and Russell, 1983). The active site-containing subunits associated with the A, B, and C classes have been shown to be the gene products of the ace-1, ace-2, and ace-3 genes, respectively (Johnson et al., 1981; Culotti et al., 1981; Kolson and Russell, 1985; Combes et al., 2000). A fourth gene, ace-4, has been described, but the protein it encodes appears not to be enzymatically active (see below).

The three AChE classes were subsequently shown to include a number of forms with different association states. Class A (ACE-1) subunits self-associate, forming amphiphilic tetramers; these tetramers may also bind to a hydrophobic noncatalytic subunit which is poorly characterized (Combes et al., 2000). Class B (ACE-2) and Class C (ACE-3) subunits form glycolipid-anchored homodimers (Combes et al., 2000). The Class C AChE activity represents only a few percent of the total C. elegans AChE activity (Kolson and Russell, 1985), yet it is noteworthy in several ways. Its apparent K_m of 16-18 nM is approximately 3 to 4 orders of magnitude lower than K_m values for Classes A and B, as well as vertebrate AChEs (Johnson and Russell, 1983; Kolson and Russell, 1985). The Class C activity is also quite resistant to cholinesterase inhibitors (Kolson and Russell, 1985). Class C-like AChE activity with these properties has been identified in other nematode species, but is not present in vertebrates (Kolson and Russell, 1985; Selkirk et al., 2005).

The three classes of AChE have quite different tissue and cellular expression patterns. Mosaic analysis was initially used to determine that ace-1 was expressed in muscles, and not (or very little) in neurons (Herman and Kari, 1985). Subsequent studies with reporter genes demonstrated expression in all body muscle cells, as well as the anal sphincter muscle, the four vm1 vulval muscles, the three pm5 pharyngeal muscles, and six neurons (2 OLL and 4 CEP; Culetto et al., 1999). Histochemical methods showed that the ACE-1 enzymatic activity was localized in or near the nerve ring and nerve cords and was presumably postsynaptic at neuromuscular junctions (Culotti et al., 1981).

Reporter analysis using an ace-2 promoter indicated expression in a number of neurons in head (including the 12 IL cells and others), neurons in the tail (PVC, PVQ, and PDA), the pm5 pharyngeal muscles, and hypodermal cells near the tip of the tail (hyp8, 9, 10, 11; Combes et al., 2003). Histochemical methods showed that the ACE-2 enzymatic activity was localized near the nerve ring and nerve cords, and also near the pharyngeointestinal valve, although the cells contributing to this pattern were not identified (Culotti et al., 1981; Combes et al., 2003).

Expression of an ace-3 reporter was observed in a few neurons in the head, a few neurons in the tail (probably PQR and PDA), the two lateral CAN cells, as well as in the pm3, pm4, pm5, and pm7 pharyngeal muscles. A dorsal row of body-wall muscle cells (the 2 dorso-medial hemiquadrants) was intensely labeled in larval stages but no longer detected in adults (Combes et al., 2003). Immunolocalization of Class C revealed staining in the nerve ring and CAN cells (there was also apparent artifactual staining of the pharyngeointestinal valve; Stern, 1986). The CAN staining in the cell processes was of a comparable intensity to the cell body, consistent with the enzyme activity being uniformly distributed in or along the plasma membrane.

It is noteworthy that although the three activities are expressed in different cell types (with the exception that all three classes are expressed in the pm5 pharyngeal muscles), all three are localized in or near the nerve ring and Classes A and B are localized in or near the ventral and dorsal nerve cords.

The three ace genes were mapped by genetic methods and are unlinked (Johnson et al., 1981; Culotti et al., 1981; Johnson et al., 1988). Subsequently, by comparing the acetylcholinesterase homologs in the genome to the known map positions of the three ace loci, it was possible to clone each of the ace genes, analyze their transcripts and expression patterns, and characterize the available mutations (Arpagaus et al., 1994; Grauso et al., 1998; Combes et al., 2000; Combes et al., 2003). Surprisingly, in the region predicted to encode ace-3 there were 2 AChE-encoding genes arranged in a two-gene operon (Grauso et al., 1998; Combes et al., 2003). Sequencing of an ace-3 mutation revealed that it was in the downstream gene; although the upstream gene (now known as ace-4) is transcribed, the encoded protein appears to be catalytically inactive (Combes et al., 2000).

Mutations have been described for ace-1, ace-2, and ace-3 (Johnson et al., 1981; Culotti et al., 1981; Johnson et al., 1988). Each of the single mutants is essentially wild-type, although ace-2 animals are hypersensitive to aldicarb. The ace-2; ace-3 and ace-3; ace-1 double mutants are also essentially wild-type (although ace-2; ace-3 animals are hypersensitive to aldicarb); however, ace-2; ace-1 animals are quite uncoordinated (Culotti et al., 1981). The ace-2; ace-3; ace-1 triple mutant is lethal - its embryonic development is apparently normal, but many of the animals do not hatch, and those that do hatch are paralyzed and developmentally arrested (Johnson et al., 1988). A potential caveat to this phenotypic analysis is that the ace-3 allele that was used was dc2, which was subsequently shown to be associated with a deletion disrupting both the ace-3 and ace-4 genes (Combes et al., 2000); thus the lethal phenotype is in reality associated with the quadruple ace-2; ace-3; ace-4; ace-1 genotype. However, since the ace-4 gene does not appear to produce a functional protein, it is likely the ace-2; ace-3; ace-1 triple mutant would have the reported lethal phenotype.

There does not appear to be any coordinated or compensatory regulation of the ace genes. In each of the three single ace mutants and each of the three double ace mutants, the remaining cholinesterase activities are present at their wild-type levels, and are not elevated (Johnson et al., 1988).

It is striking that the C. elegans genome is extraordinarily rich in genes encoding nicotinic-type receptor subunits (Mongan et al., 1998; Jones and Sattelle, 2004). Whereas mammals and birds have fewer than 20 AChR subunit genes, genetic and genomic analysis of C. elegans has thus far confirmed the transcription of 27 genes (Table 1). For some of these genes, heterologous expression individually and in combination (usually in Xenopus oocytes) has provided information about the properties of the receptor subunits; for other genes, the identity of the ligand is merely inferred. In addition, there are about 20 genes encoding putative ionotropic receptor subunits that have not been fully characterized, but could include additional AChR subunits.

Five classes of protein subunits have been identified, based on sequence similarity (see Table 1): UNC-29, UNC-38, ACR-8, ACR-16, and DEG-3 (Mongan et al., 1998; Mongan et al., 2002; Jones and Sattelle, 2004). Each class contains three to nine members, and some of the classes contain both α and non-α type subunits. The UNC-38 class contains three α subunits, and is most similar to insect a subunits. The UNC-29 class contains four non-α subunits; these proteins are similar to vertebrate skeletal muscle non-α and insect non-α subunits. The ACR-16 class consists of nine members (α and non-α), and its members resemble vertebrate α7 subunits. The ACR-8 class is α nematode specific grouping, and contains three α subunits. The DEG-3 class is also nematode specific, and consists of eight verified α and non-α subunits (there are also two genes, one α and one non-α, predicted to be in this class, but for which there are neither ESTs nor any expression data).

The best characterized C. elegans AChRs, based on electrophysiological recording and reconstitution in heterologous systems, are at neuromuscular junctions. The muscles of the body wall express two major types of ACh receptors: one type responds to levamisole and the other type responds to nicotine, but not levamisole (Richmond and Jorgensen, 1999). The levamisole-sensitive receptors on the body muscles appear to be heteromeric, and contain three essential subunits: UNC-29, UNC-38, and UNC-63 (Fleming et al., 1997; Richmond and Jorgensen, 1999; Culetto et al., 2004). LEV-1 and LEV-8 are also subunits, but they are either non-essential for the response to levamisole, or else they are only present in a subset of the receptors (Fleming et al., 1997; Towers et al., 2005). The nicotine-sensitive receptors appear to be homomeric, containing only the ACR-16 α subunit (Francis et al., 2005; Touroutine et al., 2005).

For about half of the AChR subunits, expression data from reporter studies and/or antibody localization data have been reported; in general, the different subunits appear to have complex and overlapping patterns of expression. This information is presented in Table 1.

As might be expected, loss-of-function mutations in any of the five subunits which comprise the muscle levamisole-sensitive receptor (described above) lead to levamisole resistance (Lewis et al., 1980b). However, loss-of-function mutations in unc-29, unc-38, and unc-63 confer strong levamisole resistance and a mild uncoordinated phenotype, while mutations in lev-1 and lev-8 lead to mild levamisole resistance and almost normal locomotion (Lewis et al., 1980b). In addition, acr-16 mutations, which eliminate the function of the muscle nicotine-sensitive receptor, have essentially wild-type locomotion (Francis et al., 2005; Touroutine et al., 2005). Thus, eliminating the function of either the levamisole-sensitive receptor or the nicotine-sensitive receptor does not have profound behavioral consequences. However, eliminating the function of both receptors (e.g., an unc-29; acr-16 double mutant or an unc-63;acr-16 double mutant) leads to a synthetic severe uncoordinated phenotype (Francis et al., 2005; Touroutine et al., 2005).

The deg-3 and des-2 genes are in an operon and encode similar AChR subunits (Treinin et al., 1998). There are rare dominant mutations in deg-3 that cause neuronal degeneration (presumably by hyperactivation of the channel); these mutations are suppressed by loss-of-function mutations in either des-2 or deg-3 (Treinin and Chalfie, 1995). The DEG-3 and DES-2 subunits can associate with each other to form a functional receptor in vitro (and presumably in vivo; Treinin et al., 1998). This heteromeric receptor responds more strongly to choline than acetylcholine (Yassin et al., 2001). The two genes are expressed in sensory neurons, and the DEG-3 protein is enriched in the sensory endings of these cells (Yassin et al., 2001). This suggested that the DEG-3/DES-2 receptor might play a role in sensory transduction, and deg-3 and des-2 mutants have been shown to be deficient in chemotaxis to choline (Yassin et al., 2001).

The apparent existence of muscarinic-type ACh receptors in C. elegans was first reported in 1983 (Culotti and Klein, 1983), and subsequently verified through analysis of the gar-1, gar-2, and gar-3 genes. The primary transcripts from all three of the gar genes undergo alternative splicing (Park et al., 2000; Suh et al., 2001; Park et al., 2003), leading to considerable protein diversity. Pharmacological profiles indicate that the GAR-3 isoforms are the most similar to “conventional” vertebrate muscarinic receptors, and bind the antagonist scopolamine and the agonist carbachol (Hwang et al., 1999; Park et al., 2003). The GAR-1 isoforms are somewhat different, and bind atropine, but not scopolamine (Lee et al., 1999), while GAR-2 binds neither atropine nor scopolamine (Lee et al., 2000). Complete expression profiles for these receptors have not been reported. However, GFP constructs indicated that gar-1 and gar-2 are expressed in neurons, including some sensory neurons in the head, PVM (gar-1 only), motor neurons in the ventral cord (gar-2), and HSN (gar-2) (Lee et al., 2000). gar-3 is expressed in pharyngeal muscle (Steger and Avery, 2004).

The four ACC proteins are most closely related to the C. elegans MOD-1 serotonin-gated chloride channel, and have no orthologs in vertebrate or Drosophila genomes (Putrenko et al., 2005). ACC-1 can form a homomeric ACh-gated chloride channel with an EC₅₀ of 0.26 μM, or a heteromeric channel together with ACC-3, with an EC₅₀ of 39.6 μM (Putrenko et al., 2005). ACC-2 can also form homomeric channels, with an EC₅₀ of 9.54 μM. Nothing has yet been reported about the expression patterns of these proteins, or mutant phenotypes.

This is the most important acetylcholine-mediated behavior, involving by far the greatest number of cholinergic neurons. Locomotion (both crawling on surfaces and swimming in liquid) requires the ability to generate smooth, sinusoidal waves (at variable propagation rates) of either anterior-directed or posterior-directed body muscle contractions. The involvement of ACh in locomotion includes not only neuromuscular transmission, but also nerve-nerve transmission (which is poorly characterized). Thus, for example, ventral nerve cord cholinergic motor neurons express the ACR-2 and ACR-5 AChR subunits (Winnier et al., 1999; Hallam et al., 2000), while GABAergic motor neurons express LEV-8 (Towers et al., 2005). In addition, ACh appears to be involved in the regulation of the oscillator circuit controlling the rate of wave initiation: in addition to their uncoordinated movement, cholinergic (i.e., cha-1 and unc-17) mutants have a dramatically reduced rate of wave initiation.